• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Enanta Pharmaceuticals, Inc. - Common Stock (NQ:ENTA)

    13.38 +0.16 (+1.21%)
    Streaming Delayed Price Updated: 10:50 AM EDT, Aug 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 12,772
    Open 13.27
    Bid (Size) 13.35 (100)
    Ask (Size) 13.41 (400)
    Prev. Close 13.22
    Today's Range 13.27 - 13.54
    52wk Range 6.450 - 17.15
    Shares Outstanding 21,055,392
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
    From Enanta Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
    From Enanta Pharmaceuticals, Inc.
    Via Business Wire

    Performance

    YTD
    -7.2%
    -7.2%
    1 Month
    -7.8%
    -7.8%
    3 Month
    -12.2%
    -12.2%
    6 Month
    -0.7%
    -0.7%
    1 Year
    +80.6%
    +80.6%

    More News

    Read More
    News headline image
    What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    ENANTA PHARMACEUTICALS INC (NASDAQ:ENTA) Q2 Results: Narrower Losses, Clinical Milestones in Focus ↗
    Via Chartmill
    Enanta Pharmaceuticals (NASDAQ:ENTA) Beats Q1 Estimates, Reaffirms Cash Runway Into 2029 ↗
    Via Chartmill
    News headline image
    Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
    From Enanta Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
    From Enanta Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
    From Enanta Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
    From Enanta Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
    From Enanta Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)
    From Enanta Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
    From Enanta Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
    From Enanta Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
    From Enanta Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook
    From Enanta Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From Enanta Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Enanta Pharmaceuticals Inc (NASDAQ:ENTA) Reports Mixed Q4 and Full-Year 2025 Results ↗
    Via Chartmill
    News headline image
    Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025
    From Enanta Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Earnings Scheduled For November 17, 2025 ↗
    Via Benzinga
    News headline image
    Enanta Pharma's Earnings: A Preview ↗
    Via Benzinga
    News headline image
    This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday ↗
    Via Benzinga
    News headline image
    Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Enanta Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
    From Enanta Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    12 Health Care Stocks Moving In Thursday's After-Market Session ↗
    Via Benzinga
    News headline image
    Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
    From Enanta Pharmaceuticals, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Enanta Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Enanta Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Enanta Pharmaceuticals, Inc. - Common Stock trade on?
    Enanta Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Enanta Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Enanta Pharmaceuticals, Inc. - Common Stock is ENTA on the Nasdaq Stock Market
    What is the current price of Enanta Pharmaceuticals, Inc. - Common Stock?
    The current price of Enanta Pharmaceuticals, Inc. - Common Stock is 13.38
    When was Enanta Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Enanta Pharmaceuticals, Inc. - Common Stock was at 08/06/26 10:50 AM ET
    What is the market capitalization of Enanta Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Enanta Pharmaceuticals, Inc. - Common Stock is 281.72M
    How many shares of Enanta Pharmaceuticals, Inc. - Common Stock are outstanding?
    Enanta Pharmaceuticals, Inc. - Common Stock has 282M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.